MEF2D, a member of the myocyte enhancer factor family, is aberrantly overexpressed in multiple malignancies, facilitating tumour proliferation, invasion, and drug resistance through the regulation of downstream genes (Surace et al., 2024). Here, MEF2D is linked to neoplasm.